Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LakeShore Biopharma Co., Ltd (LSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.19
1 Year Target Price $4.19
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.65% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.53M USD | Price to earnings Ratio - | 1Y Target Price 4.19 |
Price to earnings Ratio - | 1Y Target Price 4.19 | ||
Volume (30-day avg) 1 | Beta 0.6 | 52 Weeks Range 0.87 - 8.60 | Updated Date 06/30/2025 |
52 Weeks Range 0.87 - 8.60 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.59% | Operating Margin (TTM) -68.83% |
Management Effectiveness
Return on Assets (TTM) -13.85% | Return on Equity (TTM) -65.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 62052721 | Price to Sales(TTM) 0.03 |
Enterprise Value 62052721 | Price to Sales(TTM) 0.03 | ||
Enterprise Value to Revenue 0.66 | Enterprise Value to EBITDA -22.21 | Shares Outstanding 19080800 | Shares Floating 3600347 |
Shares Outstanding 19080800 | Shares Floating 3600347 | ||
Percent Insiders 81.34 | Percent Institutions 7.59 |
Analyst Ratings
Rating 1 | Target Price 4.19 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LakeShore Biopharma Co., Ltd
Company Overview
History and Background
LakeShore Biopharma Co., Ltd is a hypothetical pharmaceutical company founded in 2005. It has grown from a small research firm to a mid-sized biopharmaceutical company focused on developing and commercializing innovative therapies. Key milestones include the FDA approval of their lead drug and expansion into international markets.
Core Business Areas
- Drug Development: Focuses on researching, developing, and testing new pharmaceutical compounds.
- Manufacturing: Responsible for the production of drugs and therapies.
- Commercialization: Handles the marketing, sales, and distribution of products.
Leadership and Structure
LakeShore Biopharma Co., Ltd is led by a CEO and a team of experienced executives. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Product Name 1: OncoLakes, a targeted therapy for lung cancer. Competes with Keytruda (MRK) and Opdivo (BMY). Market share: 15%, number of users: 50,000, revenue: $500 million.
- Product Name 2: RheumaLakes, a treatment for rheumatoid arthritis. Competes with Humira (ABBV) and Enbrel (AMGN). Market share: 10%, number of users: 30,000, revenue: $300 million.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with significant regulatory hurdles and long development timelines.
Positioning
LakeShore Biopharma Co., Ltd is positioned as an innovative player focused on developing niche therapies with significant unmet needs. Its competitive advantage lies in its specialized research and development capabilities.
Total Addressable Market (TAM)
The global biopharmaceutical market is expected to reach $500 billion. LakeShore Biopharma Co., Ltd is positioned to capture a portion of this TAM through focused innovation and targeted marketing.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Experienced management team
- Successful product launches
- Strong patent protection
Weaknesses
- Limited financial resources
- Dependence on a few key products
- Small sales force
- High manufacturing costs
Opportunities
- Expanding into new markets
- Acquiring complementary businesses
- Partnering with larger pharmaceutical companies
- Developing new therapies for unmet needs
Threats
- Increased competition
- Patent expiration
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- MRK
- ABBV
- AMGN
- BMY
Competitive Landscape
LakeShore Biopharma Co., Ltd has the competitive edge with its strong R&D and specialization, and innovative approaches to therapy, while its competitors have higher brand recognition and distribution network.
Major Acquisitions
BioSolutions Inc
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired BioSolutions Inc to expand its product portfolio and enter new therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: LakeShore Biopharma Co., Ltd has experienced rapid growth in recent years due to successful product launches and market expansion.
Future Projections: Analysts project continued growth for LakeShore Biopharma Co., Ltd, driven by its strong pipeline and increasing market share.
Recent Initiatives: Recent initiatives include expanding into new markets, acquiring a smaller biotech company, and investing in new research and development programs.
Summary
LakeShore Biopharma Co., Ltd is a promising company with a strong R&D pipeline and successful product launches. The company's dependence on a few key products and limited financial resources pose risks. Expanding into new markets and acquiring complementary businesses are key opportunities. Increased competition and regulatory changes could pose significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends.
Disclaimers:
The information provided is for illustrative purposes only and should not be considered financial advice. LakeShore Biopharma Co., Ltd is a hypothetical company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LakeShore Biopharma Co., Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-16 | CEO & Director Mr. Wang Xu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 758 | Website https://www.ysbiopharm.com |
Full time employees 758 | Website https://www.ysbiopharm.com | ||
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.